Literature DB >> 22833307

Toxicity, quality of life, and functional outcomes of 176 hypopharyngeal cancer patients treated by (chemo)radiation: the impact of treatment modality and radiation technique.

Abrahim Al-Mamgani1, Robert Mehilal, Peter H van Rooij, Lisa Tans, Aniel Sewnaik, Peter C Levendag.   

Abstract

OBJECTIVES/HYPOTHESIS: The main goal of the current study was to comprehensively address the impact of chemoradiation and radiation techniques on toxicity, quality of life (QoL), and functional outcome. STUDY
DESIGN: Retrospective analysis of toxicity and functional outcome and prospective QoL assessment.
METHODS: From 1996 to 2010, 176 consecutive patients with hypopharyngeal cancer (HPC) were treated with (chemo)radiotherapy. End points were acute and late toxicity, QoL assessment, and functional outcome using laryngoesophageal dysfunction-free survival (LED-FS) defined by the Laryngeal Preservation Consensus Panel.
RESULTS: Chemoradiation significantly increased grade 3 acute toxicity compared to radiotherapy alone (71% vs. 55%, P = .02). The 3-year grade ≥2 late toxicity was 32%. Intensity-modulated radiotherapy (IMRT) significantly reduced late toxicity compared to three-dimensional conformal radiotherapy (3DCRT) (24% vs. 44%, P = .007). Slight deterioration in QoL scores was observed on almost all scales, and was more pronounced in patients treated with chemoradiation, albeit not statistically significant except for xerostomia. Chemoradiation, compared to radiotherapy alone, improved LED-FS at 3 years (51% vs. 24% for the entire group and 83% vs. 63% for the 78 living patients at last follow-up, respectively [P = .05]).
CONCLUSIONS: Compared to radiotherapy alone, chemoradiation significantly improved functional outcome, increased acute toxicity, but without significant increase in late radiation-induced side effects. Statistically significant deterioration in QoL scores was reported only for xerostomia. IMRT, compared to 3DCRT, reduced the incidence and severity of acute and late toxicity, thereby broadening the therapeutic window, and may allow dose escalation for further improvement of outcomes of laryngeal preservation protocols.
Copyright © 2012 The American Laryngological, Rhinological, and Otological Society, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22833307     DOI: 10.1002/lary.23387

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  14 in total

1.  Intensity-modulated radiotherapy for laryngeal and hypopharyngeal cancer: minimization of late dysphagia without jeopardizing tumor control.

Authors:  Anouchka Modesto; Anne Laprie; Laure Vieillevigne; Pierre Graff; Jérôme Sarini; Sébastien Vergez; Jean-Pierre Delord; Jean-Claude Farenc; Emmanuelle Vigarios; Thomas Filleron; Michel Rives
Journal:  Strahlenther Onkol       Date:  2014-11-01       Impact factor: 3.621

2.  Matched-pair analysis of patients with advanced hypopharyngeal cancer: surgery versus concomitant chemoradiotherapy.

Authors:  Shigemichi Iwae; Masato Fujii; Ryuichi Hayashi; Yasuhisa Hasegawa; Takashi Fujii; Kenji Okami; Akihiro Homma; Tetsuro Onitsuka; Takakuni Kato; Takenori Ogawa; Kyoichi Terao; Nobuya Monden; Naoki Otsuki; Hiroshi Nishino; Ichiro Ota; Yasushi Fujimoto; Kazuto Matsuura; Kazuyoshi Kawabata; Hidetoshi Matsui; Koichiro Yonezawa; Ken-Ichi Nibu
Journal:  Int J Clin Oncol       Date:  2017-06-17       Impact factor: 3.402

3.  Communication dysfunction, body image, and symptom severity in postoperative head and neck cancer patients: factors associated with the amount of speaking after treatment.

Authors:  Shu-Ching Chen; Po-Jui Yu; Ming-Ying Hong; Mei-Hui Chen; Pen-Yuan Chu; Yen-Ju Chen; Chen-Ping Wang; Yeur-Hur Lai
Journal:  Support Care Cancer       Date:  2015-01-16       Impact factor: 3.603

4.  Eliminating radiotherapy to the contralateral retropharyngeal and high level II lymph nodes in head and neck squamous cell carcinoma is safe and improves quality of life.

Authors:  Christopher R Spencer; Hiram A Gay; Bruce H Haughey; Brian Nussenbaum; Douglas R Adkins; Tanya M Wildes; Todd A DeWees; James S Lewis; Wade L Thorstad
Journal:  Cancer       Date:  2014-08-20       Impact factor: 6.860

5.  Predictors of Patient-Reported Dysphagia Following IMRT Plus Chemotherapy in Oropharyngeal Cancer.

Authors:  Ester Orlandi; Rosalba Miceli; Gabriele Infante; Aurora Mirabile; Daniela Alterio; Maria Cossu Rocca; Nerina Denaro; Riccardo Vigna-Taglianti; Annamaria Merlotti; Antonio Schindler; Nicole Pizzorni; Carlo Fallai; Lisa Licitra; Paolo Bossi
Journal:  Dysphagia       Date:  2018-06-08       Impact factor: 3.438

6.  Hypopharyngeal cancer: looking back, moving forward.

Authors:  D Day; A R Hansen; L L Siu
Journal:  Curr Oncol       Date:  2016-08-12       Impact factor: 3.677

7.  Did the addition of concomitant chemotherapy to radiotherapy improve outcomes in hypopharyngeal cancer? A population-based study.

Authors:  S F Hall; R Griffiths
Journal:  Curr Oncol       Date:  2016-08-12       Impact factor: 3.677

8.  Hypopharyngeal squamous cell carcinoma: Three-dimensional or Intensity-modulated radiotherapy? A single institution's experience.

Authors:  Evangelia Katsoulakis; Nadeem Riaz; Man Hu; Luc Morris; Eric Sherman; Sean McBride; Nancy Lee
Journal:  Laryngoscope       Date:  2015-11-24       Impact factor: 3.325

9.  Intensity-modulated radiotherapy in definitive oncological treatment of hypopharyngeal squamous cell carcinoma.

Authors:  Harri Keski-Säntti; Antti A Mäkitie; Kauko Saarilahti
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-08-08       Impact factor: 2.503

10.  Novel Manganese-Porphyrin Superoxide Dismutase-Mimetic Widens the Therapeutic Margin in a Preclinical Head and Neck Cancer Model.

Authors:  Kathleen A Ashcraft; Mary-Keara Boss; Artak Tovmasyan; Kingshuk Roy Choudhury; Andrew N Fontanella; Kenneth H Young; Gregory M Palmer; Samuel R Birer; Chelsea D Landon; Won Park; Shiva K Das; Tin Weitner; Huaxin Sheng; David S Warner; David M Brizel; Ivan Spasojevic; Ines Batinic-Haberle; Mark W Dewhirst
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-07-29       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.